Andreas H Groll

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7749839/publications.pdf

Version: 2024-02-01

176	11,993	38742 50	28297 105
papers	citations	h-index	g-index

183	183	183	8668
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
2	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
3	Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatric Infectious Disease Journal, 2002, 21, 240-248.	2.0	476
4	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017, 102, 433-444.	3.5	468
5	Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in ExperimentalCandida albicansInfection of the Central Nervous System. Journal of Infectious Diseases, 2000, 182, 274-282.	4.0	342
6	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. Journal of Clinical Oncology, 2017, 35, 2082-2094.	1.6	337
7	Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development. Advances in Pharmacology, 1998, 44, 343-500.	2.0	333
8	Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncology, The, 2014, 15, e327-e340.	10.7	325
9	Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2012, 30, 4427-4438.	1.6	311
10	Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica, 2013, 98, 492-504.	3.5	282
11	Newer Systemic Antifungal Agents. Drugs, 2004, 64, 1997-2020.	10.9	274
12	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	14.4	262
13	Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: Synergistic Interaction between an Antifungal Triazole and an Echinocandin. Journal of Infectious Diseases, 2003, 187, 1834-1843.	4.0	238
14	Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis. Pediatric Infectious Disease Journal, 2008, 27, 820-826.	2.0	196
15	Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrobial Agents and Chemotherapy, 2002, 46, 1857-1869.	3.2	178
16	The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental HematogenousCandidaMeningoencephalitis: Implications for Echinocandin Therapy in Neonates. Journal of Infectious Diseases, 2008, 197, 163-171.	4.0	168
17	Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia. Antimicrobial Agents and Chemotherapy, 2001, 45, 857-869.	3.2	162
18	Results From a Prospective, International, Epidemiologic Study of Invasive Candidiasis in Children and Neonates. Pediatric Infectious Disease Journal, 2012, 31, 1252-1257.	2.0	148

#	Article	IF	Citations
19	Utility of voriconazole therapeutic drug monitoring: a meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 1786-1799.	3.0	148
20	Clinical pharmacology of antifungal compounds. Infectious Disease Clinics of North America, 2003, 17, 159-191.	5.1	145
21	Epidemiology of Invasive Fungal Disease in Children. Journal of the Pediatric Infectious Diseases Society, 2017, 6, S3-S11.	1.3	144
22	A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia. Pediatric Infectious Disease Journal, 2010, 29, 415-420.	2.0	135
23	Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling. Antimicrobial Agents and Chemotherapy, 2001, 45, 2845-2855.	3.2	134
24	Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opinion on Investigational Drugs, 2001, 10, 1545-1558.	4.1	123
25	Galactomannan, Î²-D-Glucan, and Polymerase Chain Reactionâ€“Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2016, 63, 1340-1348.	5.8	123
26	Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. Antimicrobial Agents and Chemotherapy, 2010, 54, 4116-4123.	3.2	121
27	Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis. Antimicrobial Agents and Chemotherapy, 2002, 46, 2554-2563.	3.2	120
28	Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses, 2011, 54, 279-310.	4.0	118
29	Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infectious Diseases, 2016, 16, 667.	2.9	109
30	Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates. Antimicrobial Agents and Chemotherapy, 2005, 49, 5092-5098.	3.2	107
31	Clinical hepatotoxicity associated with antifungal agents. Expert Opinion on Drug Safety, 2017, 16, 1-17.	2.4	106
32	Pharmacokinetic Assessment of Drugâ€Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults. Clinical Pharmacology in Drug Development, 2017, 6, 76-85.	1.6	101
33	Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Review of Anti-Infective Therapy, 2005, 3, 467-487.	4.4	98
34	Toxoplasmosis in Transplant Recipients, Europe, 2010â€“2014. Emerging Infectious Diseases, 2018, 24, 1497-1504.	4.3	94
35	Drugâ€drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transplant Infectious Disease, 2017, 19, e12751.	1.7	89
36	8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncology, The, 2021, 22, e254-e269.	10.7	89

#	Article	IF	Citations
37	A Prospective, International Cohort Study of Invasive Mold Infections in Children. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 313-322.	1.3	86
38	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia, 2018, 32, 1657-1669.	7.2	86
39	Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 71, 226-236.	5.8	84
40	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	9.1	80
41	Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. Journal of Antimicrobial Chemotherapy, 2006, 57, 527-535.	3.0	75
42	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical Infectious Diseases, 2019, 68, S260-S274.	5.8	73
43	Compartmentalized Intrapulmonary Pharmacokinetics of Amphotericin B and Its Lipid Formulations. Antimicrobial Agents and Chemotherapy, 2006, 50, 3418-3423.	3.2	71
44	Antifungal Pharmacodynamics: Concentration-Effect Relationships in Vitro and in Vivo. Pharmacotherapy, 2001, 21, 133S-148S.	2.6	66
45	8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncology, The, 2021, 22, e270-e280.	10.7	65
46	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. Journal of Clinical Oncology, 2020, 38, 3205-3216.	1.6	63
47	Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in Rabbits. Antimicrobial Agents and Chemotherapy, 2001, 45, 596-600.	3.2	60
48	Antifungal chemotherapy: advances and perspectives. Swiss Medical Weekly, 2002, 132, 303-11.	1.6	60
49	Etiology and Outcome of Candidemia in Neonates and Children in Europe. Pediatric Infectious Disease Journal, 2020, 39, 114-120.	2.0	57
50	Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. Journal of Antimicrobial Chemotherapy, 2008, 61, 734-742.	3.0	53
51	Diagnostic Imaging and Invasive Fungal Diseases in Children. Journal of the Pediatric Infectious Diseases Society, 2017, 6, S22-S31.	1.3	52
52	Antifungal Chemoprophylaxis in Children and Adolescents with Haematological Malignancies and Following Allogeneic Haematopoietic Stem Cell Transplantation. Drugs, 2012, 72, 685-704.	10.9	51
53	Pneumocystis jiroveciiDisease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 72, S114-S120.	5.8	50
54	Invasive Fungal Infections in Children. Pediatric Infectious Disease Journal, 2009, 28, 734-737.	2.0	49

#	Article	IF	Citations
55	Recent Advances in Antifungal Prevention and Treatment. Seminars in Hematology, 2009, 46, 212-229.	3.4	48
56	Variability and exposureâ€“response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. Journal of Antimicrobial Chemotherapy, 2019, 74, 761-767.	3.0	48
57	Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. Journal of Antimicrobial Chemotherapy, 2009, 64, 383-387.	3.0	47
58	Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases. Mycoses, 2011, 54, e785-e788.	4.0	47
59	Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients. Antimicrobial Agents and Chemotherapy, 2012, 56, 536-543.	3.2	46
60	Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 2717-2724.	3.0	44
61	Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1664-1671.	3.2	44
62	Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. Journal of Antimicrobial Chemotherapy, 2003, 53, 113-114.	3.0	43
63	Update on antifungal agents for paediatric patients. Clinical Microbiology and Infection, 2010, 16, 1343-1353.	6.0	42
64	Safety of Micafungin in Pediatric Clinical Trials. Pediatric Infectious Disease Journal, 2011, 30, e97-e102.	2.0	42
65	Estimated burden of fungal infections in Germany. Mycoses, 2015, 58, 22-28.	4.0	42
66	Invasive Aspergillosis in Children With Acquired Immunodeficiencies. Clinical Infectious Diseases, 2012, 54, 258-267.	5.8	40
67	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clinical Infectious Diseases, 2019, 68, S244-S259.	5.8	40
68	Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. Antimicrobial Agents and Chemotherapy, 2010, 54, 4143-4149.	3.2	38
69	SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS. Pediatric Infectious Disease Journal, 2009, 28, 1132-1135.	2.0	36
70	Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opinion on Investigational Drugs, 2005, 14, 489-509.	4.1	35
71	Fatal human metapneumovirus infection following allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2013, 15, E97-E101.	1.7	35
72	Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. Antimicrobial Agents and Chemotherapy, 2016, 60, 7340-7346.	3.2	35

#	Article	IF	Citations
73	Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	35
74	Control of Multidrug-Resistant Pseudomonas aeruginosa in Allogeneic Hematopoietic Stem Cell Transplant Recipients by a Novel Bundle Including Remodeling of Sanitary and Water Supply Systems. Clinical Infectious Diseases, 2017, 65, 935-942.	5.8	34
75	Incidence and Outcome of Invasive Fungal Diseases in Children With Hematological Malignancies and/or Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Study. Frontiers in Microbiology, 2019, 10, 681.	3.5	33
76	Lipid formulations of Amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer. Klinische Padiatrie, 1998, 210, 264-273.	0.6	32
77	A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia. PLoS ONE, 2019, 14, e0212837.	2.5	32
78	SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients. European Journal of Cancer, 2021, 159, 78-86.	2.8	32
79	Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplantation, 2021, 56, 1171-1179.	2.4	30
80	Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses, 2006, 49, 7-16.	4.0	29
81	Invasive candidiasis: update on current pharmacotherapy options and future perspectives. Expert Opinion on Pharmacotherapy, 2013, 14, 1515-1528.	1.8	27
82	Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	25
83	Guidance regarding COVIDâ€19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatric Blood and Cancer, 2020, 67, e28702.	1.5	25
84	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Research and Therapy, 2020, 22, 71.	3.5	25
85	Compliance with anti-infective preventive measures: A multicentre survey among paediatric oncology patients. European Journal of Cancer, 2008, 44, 1861-1865.	2.8	24
86	Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. Journal of Antimicrobial Chemotherapy, 2005, 56, 899-907.	3.0	23
87	Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality. Antibiotics, 2021, 10, 266.	3.7	23
88	Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial. International Journal of Antimicrobial Agents, 2020, 56, 106084.	2.5	22
89	Invasive mold disease of the central nervous system in children and adolescents with cancer or undergoing hematopoietic stem cell transplantation: Analysis of 29 contemporary patients. Pediatric Blood and Cancer, 2019, 66, e27806.	1.5	21
90	Clinical pharmacology of antifungal agents in pediatric patients. Expert Opinion on Pharmacotherapy, 2007, 8, 2465-2489.	1.8	20

#	Article	IF	Citations
91	Current Algorithms in Fungal Diagnosis in the Immunocompromised Host. Methods in Molecular Biology, 2017, 1508, 67-84.	0.9	20
92	Diagnostic Approaches for Invasive Aspergillosisâ€"Specific Considerations in the Pediatric Population. Frontiers in Microbiology, 2018, 9, 518.	3.5	19
93	Invasive candidiasis and candidaemia in neonates and children: update on current guidelines. Mycoses, 2015, 58, 10-21.	4.0	18
94	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. Journal of Fungi (Basel, Switzerland), 2021, 7, 186.	3.5	18
95	Extended Dosing Regimens for Fungal Prophylaxis. Clinical Microbiology Reviews, 2019, 32, .	13.6	17
96	Posaconazole for paediatric patients: status of development and future perspectives. Mycoses, 2008, 51, 5-11.	4.0	16
97	Biomarkerâ€based diagnostic workâ€up of invasive pulmonary aspergillosis in immunocompromised paediatric patients â€" is Aspergillus PCR appropriate?. Mycoses, 2016, 59, 67-74.	4.0	16
98	Pediatric pharmacology of antifungal agents. Current Fungal Infection Reports, 2008, 2, 49-56.	2.6	15
99	Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children. Scientific Reports, 2019, 9, 12950.	3.3	15
100	Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation. Mycoses, 2020, 63, 172-180.	4.0	15
101	Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland. Infection, 2020, 48, 607-618.	4.7	15
102	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. Journal of Fungi (Basel, Switzerland), 2020, 6, 36.	3.5	15
103	Toxoplasmosis after allogeneic haematopoietic cell transplantationâ€"disease burden and approaches to diagnosis, prevention and management in adults and children. Clinical Microbiology and Infection, 2021, 27, 378-388.	6.0	15
104	Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opinion on Drug Safety, 2021, 20, 1061-1074.	2.4	15
105	When to change treatment of acute invasive aspergillosis: an expert viewpoint. Journal of Antimicrobial Chemotherapy, 2021, 77, 16-23.	3.0	15
106	Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits. Antimicrobial Agents and Chemotherapy, 2003, 47, 3917-3925.	3.2	14
107	Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates. International Journal of Antimicrobial Agents, 2006, 27, 256-258.	2.5	14
108	Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. Pharmaceutical Research, 2015, 32, 2029-2037.	3.5	13

#	Article	IF	Citations
109	Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents. Journal of Antimicrobial Chemotherapy, 2019, 74, 3573-3578.	3.0	13
110	Invasive Aspergillosis in Children and Adolescents. Current Pharmaceutical Design, 2013, 19, 3545-3568.	1.9	13
111	Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit. Journal of Antimicrobial Chemotherapy, 2014, 69, 815-820.	3.0	12
112	Cerebral toxoplasmosis in an adolescent post allogeneic hematopoietic stem cell transplantation: successful outcome by antiprotozoal chemotherapy and <scp>CD</scp>4⁺ Tâ€lymphocyte recovery. Transplant Infectious Disease, 2015, 17, 119-124.	1.7	11
113	Moraxella nonliquefaciens bloodstream infection and sepsis in a pediatric cancer patient: case report and literature review. BMC Infectious Diseases, 2019, 19, 836.	2.9	11
114	Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors. Mycoses, 2017, 60, 493-507.	4.0	10
115	Candida lusitaniae Breakthrough Fungemia in an Immuno-Compromised Adolescent: Case Report and Review of the Literature. Journal of Fungi (Basel, Switzerland), 2020, 6, 380.	3.5	10
116	Treatment of Children With Cancer and/or Hematopoietic Stem Cell Transplantation in the Intensive Care Unit: Experience at a Large European Pediatric Cancer Center. Journal of Pediatric Hematology/Oncology, 2020, 42, e583-e588.	0.6	10
117	Stenotrophomonas maltophilia Infections in Pediatric Patients â€“ Experience at a European Center for Pediatric Hematology and Oncology. Frontiers in Oncology, 2021, 11, 752037.	2.8	10
118	Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2012, 34, 460-466.	2.0	9
119	Vaccination against influenza at a European pediatric cancer center: immunization rates and attitudes among staff, patients, and their families. Supportive Care in Cancer, 2017, 25, 3815-3822.	2.2	9
120	Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10â€year experience at a European Pediatric Cancer Center. Mycoses, 2019, 62, 954-960.	4.0	9
121	Systemic viral infection in children receiving chemotherapy for acute leukemia. Pediatric Blood and Cancer, 2020, 67, e28673.	1.5	9
122	Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2019, 21, e13089.	1.7	8
123	Infectious Morbidity in Pediatric Patients Receiving Neoadjuvant Chemotherapy for Sarcoma. Cancers, 2021, 13, 1990.	3.7	8
124	Experiences with the use of caspofungin in paediatric patients. Mycoses, 2008, 51, 58-64.	4.0	7
125	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. BMC Pharmacology & Toxicology, 2020, 21, 37.	2.4	7
126	Infectious Complications in Paediatric Haematopoetic Cell Transplantation for Acute Lymphoblastic Leukemia: Current Status. Frontiers in Pediatrics, 2021, 9, 782530.	1.9	7

#	Article	IF	Citations
127	Pharmacokinetics, Safety and Efficacy of Voriconazole in Pediatric Patients: An Update. Current Fungal Infection Reports, 2012, 6, 121-126.	2.6	6
128	Systemic Antifungal Agents. , 2017, , 1333-1344.e4.		6
129	Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
130	Invasive Mold Infection of the Central Nervous System in Immunocompromised Children. Journal of Fungi (Basel, Switzerland), 2020, 6, 226.	3.5	5
131	Drug therapy in paediatric patients. Lancet, The, 2001, 357, 719.	13.7	4
132	Echinocandins. , 2011, , 95-112.		4
133	Infections during Non-Neutropenic Episodes in Pediatric Cancer Patientsâ€"Results from a Prospective Study in Two Major Large European Cancer Centers. Antibiotics, 2022, 11, 900.	3.7	4
134	Fungal infections in pediatric patients. , 2009, , 481-499.		3
135	Pre-emptive versus empirical antifungal therapy in immunocompromised children. The Lancet Child and Adolescent Health, 2019, 3, 518-520.	5.6	3
136	Durable control of hepatitis C through interferonâ€free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation. Journal of Viral Hepatitis, 2019, 26, 454-458.	2.0	3
137	Extracorporeal Membrane Oxygenation in Children With Cancer or Hematopoietic Cell Transplantation: Single-Center Experience in 20 Consecutive Patients. Frontiers in Oncology, 2021, 11, 664928.	2.8	3
138	Antimicrobial Use in Pediatric Oncology and Hematology: Protocol for a Multicenter Point-Prevalence Study With Qualitative Expert Panel Assessment. JMIR Research Protocols, 2022, 11, e35774.	1.0	3
139	Durable clearance of hepatitis B virus after allogeneic blood stem cell transplantation by adoptive immunity transfer and antiviral chemotherapy. Pediatric Infectious Disease Journal, 2003, 22, 753-755.	2.0	2
140	Efficacy and safety of antifungals in pediatric patients. Early Human Development, 2011, 87, S71-S74.	1.8	2
141	The Current Role of Posaconazole in Managing Zygomycosis. Current Fungal Infection Reports, 2011, 5, 29-33.	2.6	2
142	Clinical Pharmacology of Itraconazole in Children and Adolescents. Current Fungal Infection Reports, 2015, 9, 65-73.	2.6	2
143	Disseminated Bartonella henselae disease mimicking Langerhansâ€™ cell histiocytosis. Pediatric Blood and Cancer, 2018, 66, e27573.	1.5	2
144	Antifungal agents. , 2010, , 1477-1489.		2

#	Article	IF	Citations
145	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	2
146	Prospective surveillance of colonization and disease by methicillin-resistant Staphylococcus aureus (MRSA) at a European pediatric cancer center. Supportive Care in Cancer, 2022, 30, 7231-7239.	2.2	2
147	Antifungal drugs. Side Effects of Drugs Annual, 2008, 30, 316-335.	0.6	1
148	Caspofungin in pediatric patients. Pediatric Health, 2008, 2, 677-685.	0.3	1
149	Update on invasive opportunistic mycoses: Clinical trials review, 2008â€“2009. Current Infectious Disease Reports, 2009, 11, 417-419.	3.0	1
150	Antifungal Therapy in Pediatric Patients. Current Fungal Infection Reports, 2011, 5, 103-110.	2.6	1
151	Editorial Commentary: Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 112-115.	1.3	1
152	Antifungal Combination Therapy in Children with Cancerâ€”A 4-Year Analysis of Real-Life Data of Two Major Pediatric Cancer Centers. Journal of Fungi (Basel, Switzerland), 2021, 7, 604.	3.5	1
153	Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies. Paediatric Drugs, 2021, 23, 445-455.	3.1	1
154	Recent Developments in Epidemiology and Management of Invasive Fungal Infections. , 2003, , 191-213.		1
155	Invasive fungal infections in children: advances and perspectives. , 2007, , 405-472.		1
156	Infektionserkrankungen. , 2007, , 439-533.		1
157	1162. Antifungal Use in Immunocompromised Children in Europe: a 12-week Multicenter Modified Point prevalence Study (CALYPSO). Open Forum Infectious Diseases, 2021, 8, S672-S673.	0.9	1
158	Pharmacokinetic modelling of caspofungin to develop an extended dosing regimen in paediatric patients. Journal of Antimicrobial Chemotherapy, 2022, 77, 2209-2216.	3.0	1
159	Does posaconazole prevent invasive fungal infections in patients with neutropenia?. Nature Clinical Practice Oncology, 2007, 4, 512-513.	4.3	0
160	27 Antifungal drugs. Side Effects of Drugs Annual, 2007, 29, 280-293.	0.6	0
161	Introduction to Current Fungal Infection Reports. Current Fungal Infection Reports, 2007, 1, 1-2.	2.6	0
162	Invasive opportunistic mycoses: Clinical trials review, 2007â€“2008. Current Infectious Disease Reports, 2008, 10, 451-453.	3.0	0

#	Article	IF	Citations
163	Invasive Aspergillosis in Paediatric Patients. , 2009, , 460-483.		0
164	Antifungal drugs. Side Effects of Drugs Annual, 2010, 32, 491-519.	0.6	0
165	Medical and Adjunctive Treatment of Mucormycosis in Children: Scientific Rationale and Analysis of Cases Reported in the Literature. Current Fungal Infection Reports, 2014, 8, 12-20.	2.6	0
166	Stepâ€down and move forward. Pediatric Blood and Cancer, 2020, 67, e28342.	1.5	0
167	Therapeutic drug monitoring for antifungal triazoles: pharmacologic background and current status. Handbook of Analytical Separations, 2020, 7, 185-224.	0.8	0
168	State of Medical Mycology at German Academic Medical Centres: A Survey of the Germanâ€Speaking Mycological Society (DMYKG) and the Paulâ€Ehrlichâ€Society for Chemotherapy (PEG). Mycoses, 2021, 64, 1177-1182.	4.0	0
169	Reply to letter to the Editor to â€˜Comment about the safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrinâ€™. Expert Opinion on Drug Safety, 2021, , 1-2.	2.4	0
170	ANTIFUNGAL AGENTS. , 2009, , 3271-3308.		0
171	Antifungal Polyenes. , 0, , 389-415.		0
172	Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort. Blood, 2017, 130, 898-898.	1.4	0
173	Pediatric Invasive Fungal Infections. , 2019, , 187-203.		0
174	Mykosen bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-13.	0.0	0
175	Mykosen. Springer Reference Medizin, 2020, , 1373-1385.	0.0	0
176	School and kindergarten attendance and home schooling of pediatric cancer patients before and during the SARS-CoV-2 pandemic: results of a survey of the German Society for Pediatric Oncology and Hematology. GMS Hygiene and Infection Control, 2021, 16, Doc10.	0.3	0